ReViral – Fusion Inhibitors for RSV
ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.
9-13 January 2017
The J.P. Morgan 35th Annual Healthcare Conference
San Francisco, CA, USA
20-22 March 2017
BIO Europe Spring meeting